Press/Media
- 175 - 200 out of 789 results
Search results
-
Belgium : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
27/10/22 → 3/11/22
3 items of Media coverage
Press/Media
-
-
BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer
1/11/22
1 item of Media coverage
Press/Media
-
Tecvayli Approved for Relapsed or Refractory Multiple Myeloma
27/10/22 → 31/10/22
2 items of Media coverage
Press/Media
-
Solawave launches 1st product outside of skin tool category
31/10/22
1 item of Media coverage
Press/Media
-
Breast Cancer Research Foundation renews support for Mount Sinai Research on triple-negative breast cancer
31/10/22
3 items of Media coverage
Press/Media
-
Janssen TECVAYLI gets USFDA nod for relapsed or refractory multiple myeloma
29/10/22
1 item of Media coverage
Press/Media
-
FDA Approves Teclistamab-cqyv as First Bispecific T-cell Engager Antibody for Treatment of Patients With Relapsed or Refractory Multiple Myeloma
26/10/22
1 item of Media coverage
Press/Media
-
U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
26/10/22
2 items of Media coverage
Press/Media
-
FDA Approves Tecvayli (teclistamab-cqyv) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
26/10/22
1 item of Media coverage
Press/Media
-
FDA Approves First Bispecific Antibody for Multiple Myeloma
26/10/22
1 item of Media coverage
Press/Media
-
First Bispecific Antibody, Teclistamab, Now FDA Approved in Multiple Myeloma
25/10/22
1 item of Media coverage
Press/Media
-
-
U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
25/10/22
84 items of Media coverage
Press/Media
-
Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial to Study Pembrolizumab for Advanced NSCLC and PS 2-3
21/10/22
1 item of Media coverage
Press/Media
-
US Patent Issued to Icahn School of Medicine at Mount Sinai on Oct. 18 for "Serine threonine kinase (AKT) degradation / disruption compounds and methods of use" (New York Inventors)
Xufen Yu, Ramon Parsons & Jian Jin
19/10/22
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on the Potential Clinical Significance of Pacritinib in Myelofibrosis
18/10/22
1 item of Media coverage
Press/Media
-
Samir Parekh, MD, on Improving Survival in Multiple Myeloma With Sequential T-Cell Redirection Therapies
17/10/22
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on the Effect of Pacritinib on Anemia in Myelofibrosis
7/10/22
1 item of Media coverage
Press/Media
-
Early detection key in management of lung disease linked to trastuzumab deruxtecan
4/10/22
1 item of Media coverage
Press/Media